TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX) from its SEC filings: 2025 revenue $616.3 million (+87% vs the year before), net margin 73%, free cash flow -$25.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $616.3 million |
| Revenue growth | +87% |
| Net income | $447.2 million |
| Net margin | 72.6% |
| Free cash flow | -$25.0 million |
| Diluted EPS | $2.77 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +70% |
| Cash | $482.6 million |
| Long-term debt | $745.4 million |
| Share count, 1 year | -4% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.